Back to Search
Start Over
Vertex Announces European Commission Approval for SYMKEVI(r) (tezacaftor|ivacaftor) With KALYDECO(r) (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years
- Source :
- Plus Company Updates. November 28, 2020
- Publication Year :
- 2020
-
Abstract
- BOSTON: Vertex Pharmaceuticals Incorporated has issued the following press release: Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension for SYMKEVI(r) [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.643296422